PTDSS2

Across TCGA pan-cancer cohorts, PTDSS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTDSS2 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PTDSS2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PTDSS2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where PTDSS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.882	0.546	.004	28	view →
PDAC	DFS	Median	All	0.310	0.505	.011	11	view →
CCRCC	OS	Tertile	All	0.587	1.000	.011	6	view →
LUAD	OS	Median	III,IV	0.168	0.787	.014	3	view →
LSCC	DFS	Median	All	0.840	0.636	.021	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTDSS2–HNSC (DFS)

Open the HNSC breakdown →